CN108374035A9 - 细胞牵引力显微镜检测HeLa细胞对于诺考达唑应答的方法 - Google Patents
细胞牵引力显微镜检测HeLa细胞对于诺考达唑应答的方法 Download PDFInfo
- Publication number
- CN108374035A9 CN108374035A9 CN201810381416.0A CN201810381416A CN108374035A9 CN 108374035 A9 CN108374035 A9 CN 108374035A9 CN 201810381416 A CN201810381416 A CN 201810381416A CN 108374035 A9 CN108374035 A9 CN 108374035A9
- Authority
- CN
- China
- Prior art keywords
- cell
- elastic
- fluorescent
- nocodazole
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 title claims abstract description 28
- 229950006344 nocodazole Drugs 0.000 title claims abstract description 28
- 230000004044 response Effects 0.000 title claims abstract description 26
- 238000000034 method Methods 0.000 title claims abstract description 16
- 239000000758 substrate Substances 0.000 claims abstract description 46
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims abstract description 40
- 239000004205 dimethyl polysiloxane Substances 0.000 claims abstract description 40
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims abstract description 40
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 claims abstract description 39
- 238000004987 plasma desorption mass spectroscopy Methods 0.000 claims abstract description 39
- 238000006073 displacement reaction Methods 0.000 claims abstract description 22
- 239000002245 particle Substances 0.000 claims abstract description 11
- 230000005489 elastic deformation Effects 0.000 claims abstract 4
- 239000004005 microsphere Substances 0.000 claims description 32
- 238000002474 experimental method Methods 0.000 claims description 31
- 239000003814 drug Substances 0.000 claims description 25
- 229940079593 drug Drugs 0.000 claims description 24
- 230000000694 effects Effects 0.000 claims description 16
- 238000003556 assay Methods 0.000 claims description 12
- 239000006285 cell suspension Substances 0.000 claims description 10
- 230000000638 stimulation Effects 0.000 claims description 10
- 239000006143 cell culture medium Substances 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 7
- 239000002609 medium Substances 0.000 claims description 7
- 238000013507 mapping Methods 0.000 claims description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 5
- 108010019160 Pancreatin Proteins 0.000 claims description 5
- 238000004364 calculation method Methods 0.000 claims description 5
- 238000005119 centrifugation Methods 0.000 claims description 5
- 239000012894 fetal calf serum Substances 0.000 claims description 5
- 229940055695 pancreatin Drugs 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 238000001514 detection method Methods 0.000 abstract description 30
- 230000008569 process Effects 0.000 abstract description 4
- 238000004113 cell culture Methods 0.000 abstract description 3
- 239000007850 fluorescent dye Substances 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 description 156
- 229930012538 Paclitaxel Natural products 0.000 description 41
- 229960001592 paclitaxel Drugs 0.000 description 41
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 41
- 239000002246 antineoplastic agent Substances 0.000 description 17
- 229940044683 chemotherapy drug Drugs 0.000 description 11
- 230000000857 drug effect Effects 0.000 description 11
- 230000006907 apoptotic process Effects 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 239000000126 substance Substances 0.000 description 7
- 229940041181 antineoplastic drug Drugs 0.000 description 6
- 230000036755 cellular response Effects 0.000 description 6
- 101000699762 Homo sapiens RNA 3'-terminal phosphate cyclase Proteins 0.000 description 5
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 5
- 102100029143 RNA 3'-terminal phosphate cyclase Human genes 0.000 description 5
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000010534 mechanism of action Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 102000029749 Microtubule Human genes 0.000 description 3
- 108091022875 Microtubule Proteins 0.000 description 3
- 150000003851 azoles Chemical class 0.000 description 3
- 210000004688 microtubule Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000010282 Emodin Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 235000016408 Podocarpus macrophyllus Nutrition 0.000 description 2
- 244000162450 Taxus cuspidata Species 0.000 description 2
- 235000009065 Taxus cuspidata Nutrition 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000025084 cell cycle arrest Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- SDZRWUKZFQQKKV-JHADDHBZSA-N cytochalasin D Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@H]\3[C@]2([C@@H](/C=C/[C@@](C)(O)C(=O)[C@@H](C)C/C=C/3)OC(C)=O)C(=O)N1)=C)C)C1=CC=CC=C1 SDZRWUKZFQQKKV-JHADDHBZSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000003632 microfilament Anatomy 0.000 description 2
- 230000025090 microtubule depolymerization Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229940122937 Actin inhibitor Drugs 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- 102000002151 Microfilament Proteins Human genes 0.000 description 1
- 108010040897 Microfilament Proteins Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 231100000764 actin inhibitor Toxicity 0.000 description 1
- 238000000418 atomic force spectrum Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- UQEAIHBTYFGYIE-UHFFFAOYSA-N hexamethyldisiloxane Polymers C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- NSHPHXHGRHSMIK-IWQSFCKSSA-N latrunculin B Natural products C[C@H]1CC[C@@H]2C[C@@H](C[C@@](O)(O2)[C@@H]3CSC(=O)N3)OC(=O)C=C(C)/CCC=C/1 NSHPHXHGRHSMIK-IWQSFCKSSA-N 0.000 description 1
- NSHPHXHGRHSMIK-JRIKCGFMSA-N latrunculin B Chemical compound C([C@H]1[C@@]2(O)C[C@H]3C[C@H](O2)CC[C@@H](\C=C/CC\C(C)=C/C(=O)O3)C)SC(=O)N1 NSHPHXHGRHSMIK-JRIKCGFMSA-N 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229920005573 silicon-containing polymer Polymers 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810381416.0A CN108374035B (zh) | 2014-10-14 | 2014-10-14 | 细胞牵引力显微镜检测HeLa细胞对于诺考达唑应答的方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410538575.9A CN104359876B (zh) | 2014-10-14 | 2014-10-14 | 细胞牵引力显微镜及其在抗癌药物药效及药理检测中的应用 |
CN201810381416.0A CN108374035B (zh) | 2014-10-14 | 2014-10-14 | 细胞牵引力显微镜检测HeLa细胞对于诺考达唑应答的方法 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410538575.9A Division CN104359876B (zh) | 2014-10-14 | 2014-10-14 | 细胞牵引力显微镜及其在抗癌药物药效及药理检测中的应用 |
Publications (3)
Publication Number | Publication Date |
---|---|
CN108374035A CN108374035A (zh) | 2018-08-07 |
CN108374035A9 true CN108374035A9 (zh) | 2018-09-04 |
CN108374035B CN108374035B (zh) | 2020-04-07 |
Family
ID=52527158
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410538575.9A Active CN104359876B (zh) | 2014-10-14 | 2014-10-14 | 细胞牵引力显微镜及其在抗癌药物药效及药理检测中的应用 |
CN201810381416.0A Active CN108374035B (zh) | 2014-10-14 | 2014-10-14 | 细胞牵引力显微镜检测HeLa细胞对于诺考达唑应答的方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410538575.9A Active CN104359876B (zh) | 2014-10-14 | 2014-10-14 | 细胞牵引力显微镜及其在抗癌药物药效及药理检测中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN104359876B (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104897065A (zh) * | 2015-06-09 | 2015-09-09 | 河海大学 | 一种板壳结构表面位移场的测量系统 |
CN106338500B (zh) * | 2015-07-10 | 2019-11-01 | 北京纳米能源与系统研究所 | 细胞牵引力的测量装置、测量方法及制备方法 |
CN106483108B (zh) * | 2015-08-28 | 2020-12-01 | 北京纳米能源与系统研究所 | 细胞力学特性的测量装置及测量方法 |
CN107238661B (zh) * | 2017-05-31 | 2018-04-17 | 湖南农业大学 | 一种细胞牵引力与粘弹性的同时定量测定方法 |
CN109385460B (zh) * | 2018-11-12 | 2020-12-25 | 中国科学技术大学 | 基于单层荧光颗粒测量细胞三维牵引力的方法及系统 |
CN109827928B (zh) * | 2019-02-02 | 2019-10-11 | 东南大学 | 多模态生物力学显微镜及测量方法 |
CN111812095B (zh) * | 2020-09-08 | 2020-12-25 | 东南大学苏州医疗器械研究院 | 光子晶体显微镜和细胞力学测量方法 |
CN112461751B (zh) * | 2020-10-16 | 2022-04-26 | 江苏大学 | 基于多粘附强度融合的癌细胞活性检测评估装置与方法 |
CN115880689A (zh) * | 2021-09-26 | 2023-03-31 | 瑞新(福州)科技有限公司 | 细胞识别的方法、装置和系统 |
CN115144380B (zh) * | 2022-07-21 | 2024-08-09 | 清华大学 | 细胞牵引力的测量方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2485050B1 (en) * | 2011-02-07 | 2015-04-01 | Commissariat à l'Énergie Atomique et aux Énergies Alternatives | Use of micropatterned soft substrate for measuring of cell traction forces |
EP2780445A4 (en) * | 2011-11-16 | 2015-07-15 | Harvard College | DEFORMABLE PLATFORMS FOR BIOLOGICAL ASSAYS |
CN102539485B (zh) * | 2012-01-13 | 2014-02-19 | 武汉介观生物科技有限责任公司 | 细胞迁移高分辨率阻抗实时跟踪测控装置及其制造方法和应用方法 |
-
2014
- 2014-10-14 CN CN201410538575.9A patent/CN104359876B/zh active Active
- 2014-10-14 CN CN201810381416.0A patent/CN108374035B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN104359876B (zh) | 2018-07-10 |
CN108374035B (zh) | 2020-04-07 |
CN104359876A (zh) | 2015-02-18 |
CN108374035A (zh) | 2018-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104359876B (zh) | 细胞牵引力显微镜及其在抗癌药物药效及药理检测中的应用 | |
Bielawski et al. | Real-time force and frequency analysis of engineered human heart tissue derived from induced pluripotent stem cells using magnetic sensing | |
Xing et al. | Dynamic monitoring of cytotoxicity on microelectronic sensors | |
Suresh et al. | Connections between single-cell biomechanics and human disease states: gastrointestinal cancer and malaria | |
Schoen et al. | Probing cellular traction forces by micropillar arrays: contribution of substrate warping to pillar deflection | |
Pogoda et al. | Depth-sensing analysis of cytoskeleton organization based on AFM data | |
Suresh et al. | Reprint of: connections between single-cell biomechanics and human disease states: gastrointestinal cancer and malaria | |
Yallapu et al. | The roles of cellular nanomechanics in cancer | |
Wegener et al. | Experimental tools to monitor the dynamics of endothelial barrier function: a survey of in vitro approaches | |
Lammerding et al. | Nuclear mechanics and methods | |
EP2989460B1 (en) | Method for a cell-based drug screening assay and the use thereof | |
Feng et al. | Online analysis of drug toxicity to cells with shear stress on an integrated microfluidic chip | |
Hung et al. | Investigating the influence of anti-cancer drugs on the mechanics of cells using AFM | |
Caporizzo et al. | Strain-rate dependence of elastic modulus reveals silver nanoparticle induced cytotoxicity | |
Guo et al. | Characterization of dormant and active human cancer cells by quantitative phase imaging | |
Spencer et al. | High throughput label free measurement of cancer cell adhesion kinetics under hemodynamic flow | |
O’Connor et al. | Human brain microvascular endothelial cell pairs model tissue-level blood–brain barrier function | |
Tong et al. | Multichannel series piezoelectric quartz crystal cell sensor for real time and quantitative monitoring of the living cell and assessment of cytotoxicity | |
Shin et al. | Highly sensitive detection of epidermal growth factor receptor expression levels using a capacitance sensor | |
Weiss et al. | Mechanical compression effects on the secretion of vWF and IL-8 by cultured human vein endothelium | |
Ajetunmobi et al. | Characterization of SH‐SY5Y human neuroblastoma cell growth over glass and SU‐8 substrates | |
EP3116989A1 (en) | A novel, high-throughput, nanotopographic platform for screening cell migratory behavior | |
Raja et al. | Development path and current status of the NANIVID: a new device for cancer cell studies | |
Curtis et al. | Measuring cell forces by a photoelastic method | |
US20200033324A1 (en) | Information processing device, information processing method, and cell analyzing system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CI02 | Correction of invention patent application | ||
CI02 | Correction of invention patent application |
Correction item: Denomination of Invention|Description Correct: Detection of HeLa cell response to lobutrazol by cell traction microscopy False: Detection of Hela cell response to lobutrazol by cell traction microscopy Number: 32-01 Page: full text Volume: 34 Correction item: Denomination of Invention Correct: Detection of HeLa cell response to lobutrazol by cell traction microscopy False: Detection of Hela cell response to lobutrazol by cell traction microscopy Number: 32-01 Volume: 34 |
|
GR01 | Patent grant | ||
GR01 | Patent grant |